- $24.42m
- $16.00m
- $3.02m
TherapeuticsMD swings to Q1 net income as license revenue rises
TherapeuticsMD swings to Q3 profit, license revenue climbs
Brief: TherapeuticsMD Q1 Operating Expenses USD 1.264 Million
Brief: Therapeuticsmd - Files Lawsuit Against Mayne Pharma For Breach Of Contract
Brief: Rubric Capital Management Lp Reports 25.73% Stake In TherapeuticsMD As Of November 15
Brief: Therapeuticsmd- On Aug 17, Michael C. Donegan, Principal Financial & Accounting Officer Of Co, Notified Of His Decision To Resign From Such Positions
TherapeuticsMD Inc reports results for the quarter ended in June - Earnings Summary
Brief: TherapeuticsMD, Inc. Q2 net income from cont ops USD -2.4 million
TherapeuticsMD Inc expected to post a loss of 7 cents a share - Earnings Preview
TherapeuticsMD Inc reports results for the quarter ended in March - Earnings Summary
Brief: Therapeuticsmd Announces First Quarter 2023 Financial Results
TherapeuticsMD Inc expected to post earnings of 6 cents a share - Earnings Preview
TherapeuticsMD Inc reports results for the quarter ended in December - Earnings Summary
Brief: Therapeuticsmd Announces Full Year 2022 Financial Results And Provides Update On Business Model Transition
TherapeuticsMD Inc expected to post a loss of $1.11 a share - Earnings Preview
TherapeuticsMD Inc expected to post a loss of $1.11 a share - Earnings Preview
TherapeuticsMD Inc expected to post a loss of $1.11 a share - Earnings Preview
Brief: Therapeuticsmd Says Received Nasdaq Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule
U.S. RESEARCH ROUNDUP- Boeing, Motorola Solutions, Tractor Supply